Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Hepatic tristetraprolin promotes insulin resistance through RNA destabilization of FGF21
Konrad T. Sawicki, … , Perry J. Blackshear, Hossein Ardehali
Konrad T. Sawicki, … , Perry J. Blackshear, Hossein Ardehali
Published July 12, 2018
Citation Information: JCI Insight. 2018;3(13):e95948. https://doi.org/10.1172/jci.insight.95948.
View: Text | PDF
Research Article Metabolism

Hepatic tristetraprolin promotes insulin resistance through RNA destabilization of FGF21

  • Text
  • PDF
Abstract

The role of posttranscriptional metabolic gene regulatory programs in diabetes is not well understood. Here, we show that the RNA-binding protein tristetraprolin (TTP) is reduced in the livers of diabetic mice and humans and is transcriptionally induced in response to insulin treatment in murine livers in vitro and in vivo. Liver-specific Ttp-KO (lsTtp-KO) mice challenged with high-fat diet (HFD) have improved glucose tolerance and peripheral insulin sensitivity compared with littermate controls. Analysis of secreted hepatic factors demonstrated that fibroblast growth factor 21 (FGF21) is posttranscriptionally repressed by TTP. Consistent with increased FGF21, lsTtp-KO mice fed HFD have increased brown fat activation, peripheral tissue glucose uptake, and adiponectin production compared with littermate controls. Downregulation of hepatic Fgf21 via an adeno-associated virus–driven shRNA in mice fed HFD reverses the insulin-sensitizing effects of hepatic Ttp deletion. Thus, hepatic TTP posttranscriptionally regulates systemic insulin sensitivity in diabetes through liver-derived FGF21.

Authors

Konrad T. Sawicki, Hsiang-Chun Chang, Jason S. Shapiro, Marina Bayeva, Adam De Jesus, Brian N. Finck, Jason A. Wertheim, Perry J. Blackshear, Hossein Ardehali

×

Figure 7

Increased liver-derived circulating FGF21 is responsible for improved systemic diabetic parameters after high-fat diet in the setting of hepatic Ttp deletion.

Options: View larger image (or click on image) Download as PowerPoint
Increased liver-derived circulating FGF21 is responsible for improved sy...
(A) Fasting levels of circulating FGF21 are effectively reduced in lsTtp-KO mice injected with a hepatotropic Fgf21 shRNA AAV8 virus (shFgf21) at 3 weeks of age and then fed HFD for 12 weeks. (B and C) Downregulation of Fgf21 in lsTtp-KO mice leads to normalization of Adipoq mRNA levels in adipose tissue (B) and Slc2a1 mRNA levels in skeletal muscle (C) after HFD; n = 8 for WT shLuc and 12 for lsTtp-KO shLuc and shFgf21. *P < 0.05 by 1-way ANOVA with post hoc Fisher’s LSD test. (D–F) lsTtp-KO mice injected with Fgf21 shRNA AAV8 have reversal of glucose tolerance (D), insulin sensitivity (E), and glucose-stimulated insulin secretion (F) after HFD compared with lsTtp-KO mice injected with shLuc (n = 7 for WT shLuc, 9 for lsTtp-KO shLuc, and 16 for lsTtp-KO shFgf21 for D–F) #P < 0.05 between lsTtp-KO shFgf21 and lsTtp-KO shLuc, *P < 0.05 between lsTtp-KO shLuc and WT shLuc, $P < 0.1 between lsTtp-KO shLuc and WT shLuc. Data are presented as mean ± SEM, using 1-way ANOVA with post hoc Fisher’s LSD test.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts